Lonza and Denali Therapeutics, a San Francisco, California-headquartered biopharmaceutical company developing drugs for treating neurodegenerative diseases, have partnered for development and manufacturing for Denali’s biologic pipeline products for neurodegenerative diseases.

Through the partnership, Denali will have access to Lonza’s knowledge and technologies: from cell-line development using Lonza’s GS Xceed gene-expression system to process development and manufacturing at Lonza’s facilities in Slough, UK and Hayward, California. In addition, Lonza’s drug-product services in Basel, Switzerland will focus on ensuring that Denali’s finished-product candidates are designed with optimal formulation, stability, and delivery systems.

Denali aims to discover and develop therapies to treat degenerating diseases, including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.

Source: Lonza